## Title: Rare risk variants associate with epigenetic dysregulation in migraine

- 3 Tanya Ramdal Techlo, <sup>1</sup> Mona Ameri Chalmer, <sup>1</sup> Peter L. Møller, <sup>2</sup> Lisette J. A. Kogelman, <sup>1</sup> Isa A.
- 4 Olofsson, DBDS Genomic Consortium, Karina Banasik, Mette Nyegaard, Jes Olesen, Thomas
- 5 Folkmann Hansen\*<sup>1,3</sup>

1

2

6

- 7 <sup>1</sup>Danish Headache Center, Department of Neurology, Copenhagen University Hospital,
- 8 Rigshospitalet-Glostrup, DK-2600 Glostrup, Denmark
- 9 <sup>2</sup>Department of Biomedicine, University of Aarhus, DK-8000 Aarhus C, Denmark
- <sup>3</sup>Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, DK-2200
- 11 Copenhagen N, Denmark
- <sup>4</sup>Department of Health Science and Technology, University of Aalborg, DK-9220 Aalborg E,
- 13 Denmark

14

20

21

22

# **\*Corresponding author:**

- 16 Thomas Folkmann Hansen, Danish Headache Center, Department of Neurology, Copenhagen
- 17 University Hospital, Rigshospitalet-Glostrup, Valdemar Hansens Vej 5, DK-2600 Glostrup,
- 18 Denmark.
- 19 Phone: +45 38633051, Email: thomas.folkmann.hansen@regionh.dk

## **ABSTRACT**

- 23 Migraine has a heritability of up to 65%. Genome-wide association studies (GWAS) on migraine
- 24 have identified 123 risk loci, explaining only 10.6% of migraine heritability. Thus, there is a

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

considerable genetic component not identified with GWAS. Further, the causality of the identified risk loci remains inconclusive. Rare variants contribute to the risk of migraine but GWAS are often underpowered to detect these. Whole genome sequencing is reliable for analyzing rare variants but is not frequently used in large-scale. We assessed if rare variants in the migraine risk loci associated with migraine. We used a large cohort of whole genome sequenced migraine patients (1,040 individuals from 155 families). The findings were replicated in an independent case-control cohort (2,027 migraine patients, 1,650 controls). We found rare variants (minor allele frequency<0.1%) associated with migraine in a Polycomb Response Element in the *ASTN2* locus. The association was independent of the GWAS lead risk variant in the locus. The findings place rare variants as risk factors for migraine. We propose a biological mechanism by which epigenetic regulation by Polycomb Response Elements plays a crucial role in migraine etiology.

## **INTRODUCTION**

Migraine is a complex neurovascular and genetic disorder which affects 15-20% of the population.¹ It is characterized by episodes of severe headache, which is typically unilateral and pulsating, accompanied by nausea, vomiting, photophobia and/or phonophobia.² Identifying factors that predispose to migraine is highly relevant. The Global Burden of Disease Study (2019) ranks migraine the highest cause of disability worldwide in young women (aged 15-49) and the second highest cause of disability worldwide among both sexes.³ Additionally, migraine has a large socioeconomic impact through treatment costs and loss of productivity estimated at €27 billion in Europe alone.⁴

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

Migraine has a significant genetic component and is polygenic. There is an increased familial risk and twin studies have shown a heritability of 34%-65%. Multiple, rare variants, each with large effect sizes, may contribute to disease risk together with common variants.<sup>7,8</sup> The most recent metaanalysis of migraine genome-wide association studies (GWAS) identified 123 migraine risk loci, of which 121 were autosomal. Still, only 10.6% of the total heritability was explained by the GWAS.9 GWAS are often underpowered to detect rare variants, as these are imputed and not measured. 10 Whole genome sequencing (WGS) provides a direct assessment of rare variants. However, it is a technology that is still not frequently used in large-scale and is costly compared to genotyping using arrays. How the migraine risk loci affect migraine pathogenesis is unknown. Many reside in non-protein coding regions of the DNA and may alter the regulation of gene expression. 11 Increased risk of migraine has been linked to disruption in gene regulation<sup>12</sup> and epigenetic regulation. <sup>12–14</sup> While candidate genes have been identified for increased genetic risk in migraine, the findings have been reported with a high risk of false positive results. 15-18 This suggests that migraine pathogenesis is affected by mutations outside of protein-coding regions of the DNA, such as in regulatory regions. We hypothesized that migraine is influenced by rare variants in regulatory regions. We tested if rare variants in the migraine risk loci increase the risk of migraine. We defined blocks of linkage disequilibrium (LD) around the 121 autosomal GWAS lead risk variants using a Danish cohort of 90,312 individuals. 9,19 Within the LD-blocks, we analyzed rare variants (minor allele frequency (MAF)<0.1%, MAF<1%, and MAF<5%) in genes and regulatory regions using a Sequence Kernel Association Test. For the analysis, we used WGS data from a large cohort of 155 families (n<sub>individuals</sub>=1,040) with clustering of migraine. The findings were replicated in an independent casecontrol cohort of migraine patients with no familial history of migraine and controls.

MATERIALS AND METHODS

Migraine family cohort

The migraine family cohort consisted of 155 families with a Mendelian-like inheritance pattern of migraine. The participants were recruited from the Danish Headache Center, Rigshospitalet-Glostrup, Denmark, as described elsewhere. All participants were examined by a neurology resident or a senior medical student specifically trained in headache diagnostics. The participants were examined using a semi-structured interview based on the International Classification of Headache Disorders. The families consisted of 1,040 participants, including 746 individuals diagnosed with migraine and 294 without migraine. The mean number of participants per family was 6.7 and the mean number of migraine patients per family was 4.8. Most of the families were extended beyond the nuclear family. The smallest families consisted of at least two individuals with at least one migraine patient.

#### **Replication cohort**

The replication cohort consisted of 2,027 migraine patients with no familial history of migraine, i.e.

unrelated migraine patients, and 1,650 controls. The unrelated migraine patients were recruited and

assessed at the Danish Headache Center using the same procedures as described for the family

cohort. The controls were recruited for the Danish study of Non-Invasive testing in Coronary Artery

Disease (Dan-NICAD) according to procedures described by Nissen et al..<sup>24</sup>

## Whole genome sequencing

Blood samples were taken from all participants and genomic DNA was extracted from whole blood. The sequencing was performed on an Illumina NovaSeq 6000 sequencing platform with S4 flow cells. The WGS data was subjected to quality control by deCODE genetics, as described elsewhere.<sup>25</sup> All samples from both the migraine family cohort and the replication cohort were subjected to the same sequencing and quality control procedures.

# **Analytical approach**

## Selecting genomic regions for analysis

We calculated blocks of linkage disequilibrium (LD) around the 121 autosomal migraine risk loci, <sup>9</sup> using the genomic positions of the GWAS lead risk variants, i.e. the variants with the smallest GWAS *p*-value. For this we used 90,312 participants from the Danish Blood Donor Study (DBDS). <sup>19</sup> The genomic positions of the GWAS lead risk variants were based on SNP positions from the Database of Single Nucleotide Polymorphisms (dbSNP) build 153 in the GRCh38.p12 (hg38) assembly. The LD-blocks were calculated using a LD-block recognition algorithm proposed by Gabriel *et al.*<sup>26</sup> with PLINK2. <sup>27</sup> Here, we assessed variant-pairs within 1000 kilobases of each other with a MAF>5% using a 90% D' confidence interval threshold >0.70. Subsequently, we annotated genes and regulatory regions within the LD-blocks and analyzed these. If a LD-block partially spanned a gene or regulatory region, we included the entire gene or regulatory region in the analysis. If a LD-block was located in an intergenic region, we extended the genomic region for analysis to include the nearest protein- or RNA-coding gene. No LD-block was generated for 22

loci. In such case, the nearest protein- or RNA-coding gene was included in the analysis. The genomic positions of the regions we analyzed are found in Table S1.

## Annotating genes and regulatory regions for analysis

The gene transcripts were derived from GENCODE release 36 (basic gene-set only). They included protein-coding genes, non-coding RNA-genes, and pseudogenes. We analyzed the genes in their full length. In addition, we analyzed the coding exons, introns, 5' untranslated regions (UTR) exons, and 3' UTR exons by themselves. For regulatory regions, we analyzed promoters, enhancers, CpG islands, insulators, Polycomb Response Elements (PREs), and Transcription Factor Binding Sites (TFBSs). We included promoters from The Eukaryotic Promoter Database (EPD) version 6 and EPD non-coding promoters version 1.<sup>28</sup> The enhancers were included from the GeneHancer project,<sup>29</sup> using only enhancers that are supported by multiple studies. The genomic positions of the CpG islands were based on predictions by Gardiner-Garden *et al.*.<sup>30</sup> The insulators and PREs were included from the Broad Institute Chromatin State Segmentation by HMM<sup>31</sup> from The Encyclopedia of DNA Elements (ENCODE) Consortium<sup>32</sup> in H1-hESC cells in the GRCh37 (hg19) assembly. The TFBS were included from ENCODE<sup>32</sup> in the GRCh37 (hg19) assembly. All genomic positions in hg19 were converted to the CRCh38 (hg38) assembly. Table S2 displays the number of genes and regulatory regions that were analyzed in this study.

## Preparing VCF files for analysis

The VCF files of each participant in the study were merged into one file. Multiallelic sites were converted to a biallelic representation. Subsequently, we annotated genes and regulatory regions to

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

the merged VCF file. We isolated variants, including SNVs, insertions, and deletions, with a MAF<0.1%, MAF<1%, or MAF<5%, using BCFtools.<sup>33</sup> Rare variant association analysis To test for an association between the rare variants in genes or regulatory regions and migraine, we used the software of Family Sequence Kernel Association Test (F-SKAT).<sup>34</sup> Age and gender were used as covariates. The age was defined as the age at the time of the interview (time of diagnosis). To avoid association merely given that longer genes and regulatory regions can contain more rare variants, we used modified beta-values.<sup>35</sup> The beta-values were modified by dividing them with the length of the genes or regulatory regions. The p-values were controlled for multiple testing using the Bonferroni method based on the number of genes and regulatory regions tested. A Bonferronicorrected *p*-value<0.05 was considered significant. To assess if the results were dependent of the GWAS lead risk variants, the number of risk alleles of the variants (0, 1, or 2) were included as covariates in a separate rare variant association analysis with F-SKAT. Replication The findings were replicated using an independent cohort of unrelated migraine patients and controls. Aggregated data were available on rare variants (MAF<0.1%, MAF<1%, MAF<5%) in the genes and regulatory regions for the controls. We tested if the frequency of the rare variants was increased in the migraine patients compared with the controls, using a Fisher's Exact Test. 36 We used the null hypothesis of no association with migraine under a dominant model of penetrance.

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

The resulting p-values were controlled for multiple testing using the Bonferroni method. A Bonferroni-corrected *p*-value<0.05 was considered significant. **Characterization of findings** To explore the effect of the rare variants of the replicated results, we used Ensembl Variant Effect Predictor.<sup>37</sup> To discover the target genes of the replicated results, we used *cis*-eQTLs data from the Genotype-Tissue Expression (GTEx) version 8.0 dataset (dbGaP Accession phs000424.v8.p2 release). **Ethics** Oral and written consent was obtained from all participants. All procedures performed in studies involving human participants were in accordance with the ethical standards of the National Committee on Health Research Ethics (file no. H-2-2010-122) and with the 1964 Helsinki declaration and its later amendments. The study was approved by the data-protection agency (01080/GLO-2010-10). **RESULTS** Rare variants in regulatory regions associate with migraine We found an association between migraine and rare variants with a MAF<0.1% in 7 regulatory regions and an intron of the MACFI gene (see Table 1 for genomic regions and p-values). No

association was found for rare variants with a MAF<1% or a MAF<5% nor in coding regions (full gene transcripts, coding exons, 5' UTR exons, 3' UTR exons). In line with what is expected when analyzing rare variants for polygenic traits, 9,38,39 we found that the distribution of the test statistics deviated from the null with inflated genomic inflation factors ( $\lambda$ =1.89,  $\lambda$ =1.63, and  $\lambda$ =1.68) (Figure S1).

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

Subsequently, we replicated the Polycomb Response Element (PRE) located at chr9:117,411,901-117,412,101 in the ASTN2 locus ( $p=1.1\cdot10^{-15}$ ) using an independent case-control cohort, henceforth referred to as the replicated PRE.

We found that the findings were independent of the GWAS lead risk variants, with unaffected results ( $p=1.3\cdot10^{-4}$  in the original analysis (see Table 1) and  $p=1.2\cdot10^{-4}$  with the allele count of the risk variants as covariates).

Table 1. Summary of the results obtained from the rare variant association analysis. The results from the rare variant association analysis together with the locus ID, as given in the metaanalysis of migraine GWAS by Hautakangas et al.<sup>9</sup>, the genomic positions in GRCh38.p12 (hg38), and type of genomic feature.

Locus ID	Genomic positions	Туре	<i>p</i> -value	Corrected p-value
MACF1	chr1:39,303,078-39,309,569	Intron	1.8·10 <sup>-5</sup>	0.019
THADA	chr2:43,400,466-43,400,944	Transcription	$5.3 \cdot 10^{-6}$	0.013
		Factor Binding Site		

PHACTR1	chr6:12,748,985-12,750,439	Enhancer	1.0·10 <sup>-4</sup>	0.021
ASTN2	chr9:117,411,901-117,412,101	Polycomb	1.3·10 <sup>-4</sup>	0.012
		Response Element		
near	chr11:133,939,661-133,940,767	CpG island	1.9·10 <sup>-4</sup>	0.027
SPATA19				
	chr14:26,917,154-26,917,554	Insulator	1.2·10 <sup>-4</sup>	0.014
near LRFN5	chr14:41,610,647-41,610,847	Polycomb	6.7·10 <sup>-5</sup>	6.2·10 <sup>-3</sup>
		Response Element		
	chr14:41,610,658-41,610,787	Enhancer	$6.7 \cdot 10^{-5}$	0.028

## Rare variants in PRE map to CTCF binding sites

211

212

213

214

215

216

217

218

219

The replicated PRE was located in the first intron of the ASTN2 gene and overlapped the TFBS of CTCF, SIN3A, ZNF444, GATA2, RCOR1, and MYC (Figure 1). There were 12 rare variants with a MAF<0.1% located in the replicated PRE. These rare variants consisted of 1 SNV, 9 deletions, and 2 insertions (Table 2). We found that all rare variants mapped to CTCF binding sites (Table 2) using the Ensembl Variant Effect Predictor (VEP).




Figure 1. Overview of the genomic region around the *ASTN2* migraine risk locus. Top: The genomic region that was included for analysis (see Table S1 for genomic positions). Displayed is the GWAS lead risk variant (rs3891689), the replicated Polycomb Response Element, and the genes included for analysis. **Bottom:** A close-up of the replicated Polycomb Response Element and its surrounding genomic region. Displayed are the rare variants with a MAF<0.1%, that associated with migraine, the replicated Polycomb Response Element, near-by regulatory regions (an insulator and 17 transcription factor binding sites), the first intron of the *ASTN2* gene, and the evolutionary conservation across 100 vertebrates.

Table 2. Information on the rare variants in the replicated Polycomb Response Element. The table presents the genomic positions in GRCh38.p12 (hg38), the reference allele, the alternative

allele, the variant type, the rs number, and the Ensembl regulatory feature of the rare variants (MAF<0.1%) in the replicated Polycomb Response Element.

233

234

Genomic position	Reference allele	Alternative allele	Variant	rs number	Ensembl
			type		regulatory feature
chr9:117411967-	A	С	SNV	rs866789329	CTCF binding site
117411967					
chr9:117411977-	CCACCCCTACCA	С	Deletion		CTCF binding site
117411988					
chr9:117411978-	CACCCCTACCACCA	С	Deletion	rs158802387	CTCF binding site
117411991				2	
chr9:117411983-	CTACCA	С	Deletion	rs144647713	CTCF binding site
117411997				7	
chr9:117411983-	CTACCACCA	С	Deletion		CTCF binding site
117411991					
chr9:117411983-	CTACCACCACCCCC	С	Deletion		CTCF binding site
117411988	A				
chr9:117411990-	CA	С	Deletion		CTCF binding site
117411991					
chr9:117411996-	CACCTCACCCCT	С	Deletion		CTCF binding site
117412007					
chr9:117411999-	CTCA	С	Deletion	rs138331219	CTCF binding site
117412002				5	
chr9:117412007-	TC	Т	Deletion	rs145255224	CTCF binding site
117412008					
chr9:117412018-	A	ACCCCCCCC	Insertion		CTCF binding site
117412018					
chr9:117412018-	A	ACCCCCCCC	Insertion		CTCF binding site
117412018		С			

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258


Possible regulatory targets unidentified Finally, we assessed the possible regulatory targets of the replicated PRE. We found no significant cis-eQTLs in the PRE using the GTEx database for the identification of regulatory targets. **DISCUSSION** Our study is, to our knowledge, the first to assess if rare variants in 121 autosomal migraine risk loci increase the risk of migraine. We assessed if rare variants in genes and regulatory regions associated with migraine, using WGS data from families with clustering of migraine. We replicated a Polycomb Response Element (PRE) in the ASTN2 locus using an independent case-control cohort. Regulatory regions harbor rare variants associated with migraine We found an association between migraine and rare variants with a MAF<0.1% in 7 regulatory regions and an intron of the MACF1 gene. Our results indicate that migraine can be associated with rare variants in regulatory regions, since introns are likely to harbor elements with a regulatory function. 40 We replicated a PRE in the ASTN2 locus using an independent case-control cohort. Interestingly, we have previously reported a rare variant association with migraine in a PRE in the same locus, using a different study design. 12 Importantly, we show that the effect of the replicated PRE was independent of the GWAS lead risk variant. Thus, our results show that migraine GWAS loci also contain independent rare risk variants.

Disruption in epigenetic regulation as a possible biological mechanism for migraine

The function of mammalian PREs is still largely unknown. 41 Mammalian PREs are likely capable of binding Polycomb Group (PcG) proteins as a part of transcriptional silencing during cell division, where the silencing is maintained in subsequent daughter cells. 41–43 Associated with the silencing is remodeling of the chromatin. 44,45 Possibly, the rare variants we find associated with migraine in the replicated PRE can cause a disruption in the binding of PcG proteins and chromatin remodeling. The disruption may lead to transcriptional silencing not being maintained after cell division. This ultimately leads to an altered gene expression (Figure 2). Epigenetic mechanisms have been linked to brain plasticity in the transition from episodic to chronic migraine. 13,14 However, we are, to our knowledge, the first to report an indication of an actual biological mechanism for migraine, where chromatin remodeling is disrupted by rare variants in PREs.

We found that the rare mutations in the replicated PRE were situated in binding sites of the transcription factor CTCF. CTCF is a transcriptional repressor, with many functions including regulation of gene expression through chromatin modifications. 46 Again, our findings indicate a link to a disruption in chromatin remodeling as a biological mechanism for migraine.

# A. Normal gene expression



# B. Altered gene expression




Figure 2. Schematic overview of transcriptional silencing by PcG proteins in absence or presence of rare variants in the DNA. A. The recruitment of PcG proteins to the DNA results in transcriptional silencing that is maintained after cell division. B. A disruption of PcG binding, e.g. by rare variants, results in no binding or a weakened binding of the PcG proteins. A disrupted binding leads to an altered gene expression where gene silencing is disturbed. The altered gene expression is maintained after cell division.

#### ASTN2 as a possible regulatory target gene

We were not able to identify regulatory targets of the replicated PRE based on significant *cis*-eQTLs. Thus, the target gene could be assigned to the nearest gene, as done by Ringrose *et al.*.<sup>47</sup> The nearest gene is *ASTN2*, of which the PRE is overlapping. The *ASTN2* gene encodes the Astrotactin 2 protein. The Astrotactin 2 protein is expressed in the brain and is suggested to play a

part in neuronal migration. Thus, our findings support the hypothesis of migraine being a neuronal

disorder.48

## Implications for genetic studies on migraine

The most recent meta-analysis of migraine GWAS only explains 10.6% of the total heritability of migraine. GWAS are often underpowered to detect rare variants with low-penetrant alleles. We found that migraine associated with very rare variants, i.e. variants with a MAF<0.1%, in the migraine risk loci. Our results indicate that a part of the unexplained heritability of migraine could arise from rare variants not detected by GWAS. Also, our results suggest that the unexplained heritability could be hidden in epigenetics. For discovering the unexplained heritability of migraine, future studies focusing on the identification of heritable epigenetic marks for migraine can be highly relevant.

## **CONCLUSION**

We found that rare variants (MAF<0.1%) in a Polycomb Response Element in the *ASTN2* locus associated with migraine. The association was independent of the original, common variant in the locus. Thus, migraine GWAS loci also contain independent rare risk variants. We propose a biological mechanism for migraine by which chromatin remodeling is disrupted by rare variants in Polycomb Response Elements.

#### **ABBREVIATIONS**

315 **GWAS** Genome-Wide Association Study Linkage disequilibrium LD 316 317 MAF Minor allele frequency PcG Polycomb Group protein 318 **PRE** Polycomb Response Element 319 **TFBS** Transcription factor binding site 320 UTR Untranslated region 321 322 WGS Whole genome sequencing 323 **FUNDING** 324 325 The study was funded by a grant from Candys Foundation "CEHEAD" and a grant from Jascha 326 Fonden (web site: https://jaschafonden.dk/). The funders had no role in study design, data collection 327 and analysis, decision to publish, or preparation of the manuscript. 328 329 330 **COMPETING INTERESTS** 331 The authors have declared that no competing interests exist. 332 333 **DATA AVAILABILITY** 334 335 336 The data supporting the conclusions of this article are unavailable, as they contain information that may be used for identifying study participants. However, summary data supporting the conclusions 337 of this article are available on request to the corresponding author of this article. 338

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

**ACKNOWLEDGEMENTS** We thank deCODE genetics for whole genome sequencing and quality-controlling our samples. We thank the Danish blood donors for their valuable participation in the Danish Blood Donor Study as well as the staff at the blood centers for making this study possible. Finally, we thank all of the staff and participating patients at the Danish Headache Center for their willing assistance. **CONSORTIA** Members list of the DBDS Genomic Consortium: Steffen Andersen<sup>1</sup>, Karina Banasik<sup>2</sup>, Søren Brunak<sup>2</sup>, Kristoffer Burgdorf<sup>3</sup>, Christian Erikstrup<sup>4</sup>, Thomas Folkmann Hansen<sup>5</sup>, Henrik Hjalgrim<sup>6</sup>, Gregor Jemec<sup>7</sup>, Poul Jennum<sup>8</sup>, Per Ingemar Johansson<sup>3</sup>, Kasper Rene Nielsen<sup>9</sup>, Mette Nyegaard<sup>10</sup>, Mie Topholm Bruun<sup>11</sup>, Ole Birger Pedersen<sup>12</sup>, Susan Mikkelsen<sup>4</sup>, Khoa Manh Dinh<sup>4</sup>, Erik Sørensen<sup>3</sup>, Henrik Ullum<sup>3</sup>, Sisse Ostrowski<sup>3</sup>, Thomas Werge<sup>13</sup>, Daniel Gudbjartsson<sup>14</sup>, Kari Stefansson<sup>14</sup>, Hreinn Stefansson<sup>14</sup>, Unnur Þorsteinsdóttir<sup>14</sup>, Margit Anita Hørup Larsen<sup>3</sup>, Marja Didriksen<sup>3</sup>, Susanne Sækmose<sup>12</sup>. <sup>1</sup> Department of Finance, Copenhagen Business School, Copenhagen, Denmark. <sup>2</sup> Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark <sup>3</sup> Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark <sup>4</sup> Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark

- <sup>5</sup> Danish Headache Center, Department of Neurology, Copenhagen University Hospital, Glostrup, 362
- Denmark 363
- <sup>6</sup> Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark 364
- <sup>7</sup> Department of Clinical Medicine, Sealand University Hospital, Roskilde, Denmark 365
- <sup>8</sup> Department of Clinical Neurophysiology, University of Copenhagen, Copenhagen, Denmark 366
- <sup>9</sup> Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark 367
- <sup>10</sup> Department of Biomedicine, Aarhus University, Aarhus, Denmark 368
- <sup>11</sup> Department of Clinical Immunology, Odense University Hospital, Odense, Denmark 369
- <sup>12</sup> Department of Clinical Immunology, Næstved Hospital, Næstved, Denmark 370
- <sup>13</sup> Institute of Biological Psychiatry, Mental Health Centre Sct. Hans, Copenhagen University 371
- 372 Hospital, Roskilde, Denmark
- <sup>14</sup> deCODE genetics, Revkiavik, Iceland 373

#### **REFERENCES**

374

375

376

- 1. Stovner, L. J. et al. Global, regional, and national burden of migraine and tension-type 377
- headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. 378
- Lancet Neurol. 17, 954-976 (2018). 379
- Headache Classification Committee of the International Headache Society (IHS) The 2. 380
- International Classification of Headache Disorders, 3rd edition. Cephalalgia 38, 1–211 381
- (2018).382
- 383 3. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a
- systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England) 384
- **396**, 1204–1222 (2020). 385

- 386 4. Stovner, L. J. & Andrée, C. Impact of headache in Europe: a review for the Eurolight project
- On behalf of the Eurolight Steering Committee. *J Headache Pain* **9**, 139–146 (2008).
- 388 5. Mulder, E. J. et al. Genetic and environmental influences on migraine: a twin study across
- six countries. *Twin Res* **6**, 422–431 (2003).
- 390 6. Ulrich, V., Gervil, M., Kyvik, K. O., Olesen, J. & Russell, M. B. The inheritance of migraine
- with aura estimated by means of structural equation modelling. J. Med. Genet. 36, 225–227
- 392 (1999).
- 393 7. Hansen, R. D., Christensen, A. F. & Olesen, J. Family studies to find rare high risk variants
- in migraine. *J Headache Pain* **18**, 32 (2017).
- 395 8. Levy, D., Strassman, A. M. & Burstein, R. A critical view on the role of migraine triggers in
- the genesis of migraine pain. *Headache* **49**, 953–957 (2009).
- 9. Hautakangas, H. et al. Genome-wide analysis of 102,084 migraine cases identifies 123 risk
- loci and subtype-specific risk alleles. *medRxiv* 2021.01.20.21249647 (2021)
- 399 doi:10.1101/2021.01.20.21249647.
- 400 10. Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747–
- 401 753 (2009).
- 402 11. Nicolae, D. L. et al. Trait-associated SNPs are more likely to be eQTLs: annotation to
- enhance discovery from GWAS. *PLoS Genet* **6**, e1000888 (2010).
- 404 12. Techlo, T. R. et al. Familial analysis reveals rare risk variants for migraine in regulatory
- regions. *Neurogenetics* (2020) doi:10.1007/s10048-020-00606-5.
- 406 13. Eising, E., A Datson, N., van den Maagdenberg, A. M. J. M. & Ferrari, M. D. Epigenetic
- 407 mechanisms in migraine: a promising avenue? *BMC Med.* 11, 26 (2013).
- 408 14. Winsvold, B. S. et al. Epigenetic DNA methylation changes associated with headache
- 409 chronification: A retrospective case-control study. *Cephalalgia* **38**, 312–322 (2018).

- 410 15. Corominas, R. et al. Association study of the serotoninergic system in migraine in the
- Spanish population. Am. J. Med. Genet. Part B, Neuropsychiatr. Genet. Off. Publ. Int. Soc.
- 412 *Psychiatr. Genet.* **153B**, 177–184 (2010).
- 413 16. Lafreniere, R. G. et al. A dominant-negative mutation in the TRESK potassium channel is
- linked to familial migraine with aura. *Nat Med* **16**, 1157–1160 (2010).
- 17. Nyholt, D. R. et al. A high-density association screen of 155 ion transport genes for
- involvement with common migraine. Hum. Mol. Genet. 17, 3318–3331 (2008).
- 417 18. de Vries, B. et al. Systematic re-evaluation of genes from candidate gene association studies
- in migraine using a large genome-wide association data set. Cephalalgia 36, 604–614
- 419 (2016).
- 420 19. Hansen, T. F. et al. DBDS Genomic Cohort, a prospective and comprehensive resource for
- 421 integrative and temporal analysis of genetic, environmental and lifestyle factors affecting
- health of blood donors. *BMJ Open* **9**, e028401 (2019).
- 423 20. Chalmer, M. A., Hansen, T. F. & Olesen, J. Nosographic analysis of osmophobia and field
- testing of diagnostic criteria including osmophobia. *Cephalalgia* **39**, 38–43 (2019).
- 425 21. Eriksen, M. K., Thomsen, L. L., Andersen, I., Nazim, F. & Olesen, J. Clinical characteristics
- of 362 patients with familial migraine with aura. Cephalalgia 24, 564–575 (2004).
- 427 22. Gervil, M., Ulrich, V., Olesen, J. & Russell, M. B. Screening for migraine in the general
- population: validation of a simple questionnaire. *Cephalalgia* **18**, 342–348 (1998).
- 429 23. Rasmussen, B. K., Jensen, R. & Olesen, J. Questionnaire versus clinical interview in the
- diagnosis of headache. *Headache* **31**, 290–295 (1991).
- 431 24. Nissen, L. et al. Danish study of Non-Invasive testing in Coronary Artery Disease (Dan-
- NICAD): study protocol for a randomised controlled trial. *Trials* 17, 262 (2016).
- 433 25. Jonsson, H. *et al.* Whole genome characterization of sequence diversity of 15,220 Icelanders.

- 434 Sci. data 4, 170115 (2017).
- 435 26. Gabriel, S. B. et al. The structure of haplotype blocks in the human genome. Science 296,
- 436 2225–2229 (2002).
- 437 27. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based
- 438 linkage analyses. *Am J Hum Genet* **81**, 559–575 (2007).
- 28. Dreos, R., Ambrosini, G., Cavin Perier, R. & Bucher, P. EPD and EPDnew, high-quality
- promoter resources in the next-generation sequencing era. *Nucleic Acids Res* **41**, D157-64
- 441 (2013).
- 442 29. Fishilevich, S. et al. GeneHancer: genome-wide integration of enhancers and target genes in
- 443 GeneCards. *Database (Oxford)* **2017**, (2017).
- 444 30. Gardiner-Garden, M. & Frommer, M. CpG islands in vertebrate genomes. J Mol Biol 196,
- 445 261–282 (1987).
- 446 31. Ernst, J. & Kellis, M. Discovery and characterization of chromatin states for systematic
- annotation of the human genome. *Nat Biotechnol* **28**, 817–825 (2010).
- 448 32. Gerstein, M. B. et al. Architecture of the human regulatory network derived from ENCODE
- data. *Nature* **489**, 91–100 (2012).
- 450 33. Li, H. A statistical framework for SNP calling, mutation discovery, association mapping and
- population genetical parameter estimation from sequencing data. *Bioinformatics* **27**, 2987–
- 452 2993 (2011).
- 453 34. Yan, Q. et al. A Sequence Kernel Association Test for Dichotomous Traits in Family
- Samples under a Generalized Linear Mixed Model. *Hum Hered* **79**, 60–68 (2015).
- 455 35. Wu, M. C. *et al.* Rare-variant association testing for sequencing data with the sequence
- kernel association test. Am J Hum Genet 89, 82–93 (2011).
- 457 36. Fisher, R. A. Statistical methods for research workers. (Oliver and Boyd) (1934).

- 458 37. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol 17, 122 (2016).
- 459 38. Mathieson, I. & McVean, G. Differential confounding of rare and common variants in
- spatially structured populations. *Nat Genet* **44**, 243–246 (2012).
- 461 39. Pirie, A., Wood, A., Lush, M., Tyrer, J. & Pharoah, P. D. The effect of rare variants on
- inflation of the test statistics in case-control analyses. *BMC Bioinformatics* **16**, 53 (2015).
- 463 40. Maston, G. A., Evans, S. K. & Green, M. R. Transcriptional regulatory elements in the
- human genome. Annu Rev Genomics Hum Genet 7, 29–59 (2006).
- 465 41. Klymenko, T. & Müller, J. The histone methyltransferases Trithorax and Ash1 prevent
- 466 transcriptional silencing by Polycomb group proteins. *EMBO Rep.* **5**, 373–377 (2004).
- 467 42. Reinig, J., Ruge, F., Howard, M. & Ringrose, L. A theoretical model of Polycomb/Trithorax
- action unites stable epigenetic memory and dynamic regulation. *Nat. Commun.* **11**, 4782
- 469 (2020).
- 470 43. Chan, C. S., Rastelli, L. & Pirrotta, V. A Polycomb response element in the Ubx gene that
- determines an epigenetically inherited state of repression. *EMBO J.* **13**, 2553–2564 (1994).
- 472 44. Kalb, R. et al. Histone H2A monoubiquitination promotes histone H3 methylation in
- 473 Polycomb repression. *Nat. Struct. Mol. Biol.* **21**, 569–571 (2014).
- 474 45. Cao, R. et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science
- **298**, 1039–1043 (2002).
- 476 46. Phillips, J. E. & Corces, V. G. CTCF: master weaver of the genome. *Cell* 137, 1194–1211
- 477 (2009).
- 478 47. Ringrose, L., Rehmsmeier, M., Dura, J.-M. & Paro, R. Genome-wide prediction of
- 479 Polycomb/Trithorax response elements in Drosophila melanogaster. *Dev. Cell* **5**, 759–771
- 480 (2003).
- 481 48. Goadsby, P. J. Pathophysiology of migraine. *Neurol Clin* 27, 335–360 (2009).